Doximity (NYSE:DOCS) Stock Price Down 8.4% on Insider Selling

15 May 2026, 15:34 by Doug Wharley · The Cerbat Gem

Doximity, Inc. (NYSE:DOCS – Get Free Report)’s stock price dropped 8.4% on Wednesday after an insider sold shares in the company. The stock traded as low as $24.57 and last traded at $24.2360. Approximately 2,318,256 shares changed hands during trading, a decline of 31% from the average daily volume of 3,348,805 shares. The stock had previously closed at $26.45.

Specifically, insider Siddharth Sitaram sold 2,309 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $25.77, for a total value of $59,502.93. Following the transaction, the insider owned 89,396 shares in the company, valued at approximately $2,303,734.92. This represents a 2.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Scherer Wampler sold 9,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $26.06, for a total transaction of $234,540.00. Following the sale, the director owned 19,839 shares of the company’s stock, valued at $517,004.34. This trade represents a 31.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Ratings Changes

DOCS has been the topic of several research reports. Loop Capital set a $31.00 target price on Doximity in a research report on Tuesday, March 17th. Bank of America reduced their price target on Doximity from $56.00 to $47.00 and set a “buy” rating for the company in a research note on Thursday, April 16th. Zacks Research raised Doximity from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 21st. KeyCorp cut Doximity from an “overweight” rating to a “sector weight” rating in a research report on Thursday. Finally, Canaccord Genuity Group reduced their target price on shares of Doximity from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and fourteen have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.62.

Read Our Latest Analysis on DOCS

Doximity News Summary

Here are the key news stories impacting Doximity this week:

Positive Sentiment: Doximity reported adjusted EPS of $0.26 and revenue of $145.37 million, with revenue up 5.1% year over year, showing the business is still expanding. Doximity Earnings Report
Positive Sentiment: The company also announced a partnership with Aledade to integrate AI-powered documentation and clinical search tools into physician workflows, supporting its long-term AI strategy. DOCS Teams Up With Aledade
Neutral Sentiment: Some commentary argues DOCS may be technically oversold after a sharp recent selloff, which could set up a rebound if sentiment stabilizes. DOCS Looks Ripe for a Turnaround
Neutral Sentiment: Doximity also drew a valuation comparison article versus Hims & Hers, reflecting continued investor focus on whether DOCS is cheap enough after the selloff. DOCS vs. HIMS Article
Negative Sentiment: Fiscal 2027 revenue guidance of $664 million to $676 million fell short of analyst estimates around $696 million, fueling concern about slower growth ahead. Doximity Q4 2026 Earnings Call Transcript
Negative Sentiment: Analysts turned cautious, with several firms cutting price targets and multiple downgrades landing after the earnings release, including Robert W. Baird and Wells Fargo shifting to hold. Analyst Coverage
Negative Sentiment: Recent insider selling and unusual put buying added to the bearish tone, even though the insider sale was part of a pre-arranged 10b5-1 plan. Insider Trade Disclosure

Doximity Trading Up 2.7%

The company has a market cap of $3.42 billion, a P/E ratio of 18.75, a P/E/G ratio of 1.66 and a beta of 1.36. The firm has a 50-day simple moving average of $24.09.

Doximity announced that its board has initiated a stock buyback program on Thursday, February 5th that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 8% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Doximity by 4.1% in the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock valued at $588,281,000 after acquiring an additional 518,916 shares during the last quarter. Aubrey Capital Management Ltd bought a new position in shares of Doximity in the third quarter worth about $4,572,000. UBS Group AG lifted its holdings in shares of Doximity by 26.5% in the fourth quarter. UBS Group AG now owns 680,260 shares of the company’s stock worth $30,122,000 after acquiring an additional 142,408 shares during the last quarter. Blair William & Co. IL boosted its stake in shares of Doximity by 1,990.7% in the 3rd quarter. Blair William & Co. IL now owns 362,740 shares of the company’s stock valued at $26,534,000 after purchasing an additional 345,390 shares in the last quarter. Finally, William Blair Investment Management LLC boosted its stake in shares of Doximity by 11.7% in the 3rd quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock valued at $426,404,000 after purchasing an additional 609,775 shares in the last quarter. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Doximity Company Profile

(Get Free Report)

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.